Winthrop Partners - WNY’s Teva Pharmaceuticals TEVA Stock Holding History

Winthrop Partners - WNY’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$2.75K	Hold	400	–	–	﹤0.01%	283
2019 Q2	$3.69K	Hold	400	–	–	﹤0.01%	215
2019 Q1	$6.29K	Hold	400	–	–	﹤0.01%	211
2018 Q4	$6.17K	Hold	400	–	–	0.01%	220
2018 Q3	$8.62K	Hold	400	–	–	0.01%	248
2018 Q2	$9.73K	Sell	400 -1,000	-71%	-$20.4K	0.01%	255
2018 Q1	$24K	Buy	+1,400	New	+$27.3K	0.02%	263

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return

Winthrop Partners - WNY's TEVA Position: Q3 2019 in Review

Winthrop Partners - WNY held its Teva Pharmaceuticals (TEVA) position steady in Q3 2019 at 400 shares worth $2.75K. The position accounts for ﹤0.01% of the portfolio, ranked #283.

Winthrop Partners - WNY first reported a position in TEVA in Q1 2018 and has held it in 7 quarters since. The position peaked at $24K in Q1 2018. 427 funds tracked by Wall St. Rank hold TEVA as of Q3 2019.

Winthrop Partners - WNY held 400 shares of Teva Pharmaceuticals worth $2.75K as of Q3 2019.
Winthrop Partners - WNY left its Teva Pharmaceuticals share count unchanged in Q3 2019.
Teva Pharmaceuticals made up ﹤0.01% of Winthrop Partners - WNY's portfolio in Q3 2019, its #283 holding.
Winthrop Partners - WNY first reported a position in Teva Pharmaceuticals in Q1 2018 and has held it in 7 quarters since.
Winthrop Partners - WNY's Teva Pharmaceuticals position peaked at $24K in Q1 2018.
427 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2019.

Based on Winthrop Partners - WNY's 13F filing for Q3 2019, filed 28 Oct 2019.